+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Exosome Diagnostic and Therapeutic Market Size, Share & Industry Trends Analysis Report By Application, By Product, By End User, By Country and Growth Forecast, 2022 - 2028

  • PDF Icon

    Report

  • 77 Pages
  • May 2022
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5615870
The Europe Exosome Diagnostic and Therapeutic Market is expected to witness market growth of 26.2% CAGR during the forecast period (2022-2028).

Exosomes are nanovesicles that are part of an intercellular communication system. Their features appear potential as a biomarker in cancer research, which urgently requires more sophisticated monitoring and therapeutic applications. Overall survival in the case of head and neck squamous cell carcinoma (HNSCC) is generally poor, despite significant technological advances in the treatment of this illness. Diagnostic and therapeutic qualities are highlighted and summarized in the following review. Although the initial results are promising, additional research is needed before these revolutionary procedures can be implemented into daily clinical practice. 

Exosomes had been widely dismissed as a form of cellular trash and had been forgotten for decades. When their capabilities for intercellular communication, involvement with the immune system, and potential use as a drug vector were discovered, everything changed. The precise definition of exosomes has sparked a lot of debate to date.

In Europe, cardiovascular diseases (CVD) continue to be the primary cause of death, accounting for 45 percent of all deaths. Every year, more than 4 million Europeans die from cardiovascular disease (CVD), primarily from CHD and stroke. Many more are admitted to hospitals, and many more acquire long-term disabilities that necessitate lifetime therapy. CVD has huge economic ramifications for Europe, in addition to human misery. CVD is predicted to cost the EU economy €210 billion per year, which includes direct health-care expenditures as well as non-health costs such as lost productivity and informal care for people with CVD. The cardiovascular disease mortality rate in Central and Eastern Europe is the highest in the world.

The Germany market dominated the Europe Exosome Diagnostic and Therapeutic Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $96.9 million by 2028. The UK market is estimated to grow at a CAGR of 25.2% during (2022 - 2028). Additionally, The France market is expected to exhibit a CAGR of 27.2% during (2022 - 2028).

Based on Application, the market is segmented into Diagnostic and Therapeutic. Based on Product, the market is segmented into Reagent, Instrument, and Software. Based on End User, the market is segmented into Cancer Institute, Hospital, Diagnostic Center, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Qiagen N.V., Thermo Fisher Scientific, Inc., Aethlon Medical, Inc., Capricor Therapeutics, Inc., Malvern Panalytical Ltd., NanoSomix, Inc., System Biosciences, LLC, and NX Pharmagen, Inc.

Scope of the Study


Market Segments Covered in the Report:


By Application

  • Diagnostic
  • Therapeutic

By Product

  • Reagent
  • Instrument
  • Software

By End User

  • Cancer Institute
  • Hospital
  • Diagnostic Center
  • Others

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players


List of Companies Profiled in the Report:

  • Bio-Techne Corporation
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Aethlon Medical, Inc.
  • Capricor Therapeutics, Inc.
  • Malvern Panalytical Ltd.
  • NanoSomix, Inc.
  • System Biosciences, LLC
  • NX Pharmagen, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Exosome Diagnostic and Therapeutic Market, by Application
1.4.2 Europe Exosome Diagnostic and Therapeutic Market, by Product
1.4.3 Europe Exosome Diagnostic and Therapeutic Market, by End User
1.4.4 Europe Exosome Diagnostic and Therapeutic Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Exosome Diagnostic and Therapeutic Market
Chapter 4. Europe Exosome Diagnostic and Therapeutic Market by Application
4.1 Europe Diagnostic Market by Country
4.2 Europe Therapeutic Market by Country
Chapter 5. Europe Exosome Diagnostic and Therapeutic Market by Product
5.1 Europe Reagent Market by Country
5.2 Europe Instrument Market by Country
5.3 Europe Software Market by Country
Chapter 6. Europe Exosome Diagnostic and Therapeutic Market by End User
6.1 Europe Cancer Institute Market by Country
6.2 Europe Hospital Market by Country
6.3 Europe Diagnostic Center Market by Country
6.4 Europe Others Market by Country
Chapter 7. Europe Exosome Diagnostic and Therapeutic Market by Country
7.1 Germany Exosome Diagnostic and Therapeutic Market
7.1.1 Germany Exosome Diagnostic and Therapeutic Market by Application
7.1.2 Germany Exosome Diagnostic and Therapeutic Market by Product
7.1.3 Germany Exosome Diagnostic and Therapeutic Market by End User
7.2 UK Exosome Diagnostic and Therapeutic Market`
7.2.1 UK Exosome Diagnostic and Therapeutic Market by Application
7.2.2 UK Exosome Diagnostic and Therapeutic Market by Product
7.2.3 UK Exosome Diagnostic and Therapeutic Market by End User
7.3 France Exosome Diagnostic and Therapeutic Market
7.3.1 France Exosome Diagnostic and Therapeutic Market by Application
7.3.2 France Exosome Diagnostic and Therapeutic Market by Product
7.3.3 France Exosome Diagnostic and Therapeutic Market by End User
7.4 Russia Exosome Diagnostic and Therapeutic Market
7.4.1 Russia Exosome Diagnostic and Therapeutic Market by Application
7.4.2 Russia Exosome Diagnostic and Therapeutic Market by Product
7.4.3 Russia Exosome Diagnostic and Therapeutic Market by End User
7.5 Spain Exosome Diagnostic and Therapeutic Market
7.5.1 Spain Exosome Diagnostic and Therapeutic Market by Application
7.5.2 Spain Exosome Diagnostic and Therapeutic Market by Product
7.5.3 Spain Exosome Diagnostic and Therapeutic Market by End User
7.6 Italy Exosome Diagnostic and Therapeutic Market
7.6.1 Italy Exosome Diagnostic and Therapeutic Market by Application
7.6.2 Italy Exosome Diagnostic and Therapeutic Market by Product
7.6.3 Italy Exosome Diagnostic and Therapeutic Market by End User
7.7 Rest of Europe Exosome Diagnostic and Therapeutic Market
7.7.1 Rest of Europe Exosome Diagnostic and Therapeutic Market by Application
7.7.2 Rest of Europe Exosome Diagnostic and Therapeutic Market by Product
7.7.3 Rest of Europe Exosome Diagnostic and Therapeutic Market by End User
Chapter 8. Company Profiles
8.1 Bio-Techne Corporation (Exosome Diagnostic, Inc.)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.2 Qiagen N.V.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expense
8.3 Thermo Fisher Scientific, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Aethlon Medical, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.5 Capricor Therapeutics, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.5.4 Recent strategies and developments:
8.5.4.1 Partnerships, Collaborations, and Agreements:
8.6 Malvern Panalytical Ltd. (Spectris plc)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.7 Nanosomix, Inc.
8.7.1 Company Overview
8.8 System Biosciences, LLC
8.8.1 Company Overview
8.9 NX Pharmagen, Inc. (NX Prenatal, Inc.)
8.9.1 Company Overview

Companies Mentioned

  • Bio-Techne Corporation
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Aethlon Medical, Inc.
  • Capricor Therapeutics, Inc.
  • Malvern Panalytical Ltd.
  • NanoSomix, Inc.
  • System Biosciences, LLC
  • NX Pharmagen, Inc.

Methodology

Loading
LOADING...